Miller Anestesia

the skeletal muscle ryanodine receptor. J Gen

Physiol 118:277-290, 2001.

193. Avila G, O’Brien JJ, Dirksen RT: Excitation-contrac-

tion uncoupling by a human central core disease

mutation in the ryanodine receptor. Proc Natl Acad

Sci USA 98:4215-4220, 2001.

194. Avila G, O’Connell KM, Dirksen RT: The pore region

of the skeletal muscle ryanodine receptor is a primary

locus for excitation-contraction uncoupling in central

core disease. J Gen Physiol 121:277-286, 2003.

195. Dirksen RT, Avila G: Altered ryanodine receptor

function in central core disease: Leaky or uncoupled

+ release channels? Trends Cardiovasc Med

12:189-197, 2002.

196. Weiss RG,O’Connell KM,Flucher BE,et al: Functio-

nal analysis of the R1086Hmalignant hyperthermia

mutation in the DHPR reveals an unexpected

influence of the III-IV loop on skeletal muscle EC

coupling. Am J Physiol Cell Physiol 287:C1094-

C1102, 2004.

197. Ikemoto N, Yamamoto T: Regulation of calcium

release by interdomain interaction within ryano-

dine receptors. Front Biosci 7:d671-d683, 2002.

198. Jones DE, Ryan JF, Taylor B, et al: Pancuronium in

large doses protects susceptible swine from halo-

thane induced malignant hyperthermia. Anesthe-

siology 63:A344, 1985.

199. Hurne AM,O’Brien JJ,Wingrove D,et al: Ryanodine

receptor type 1 (RyR1) mutations C4958S and

C4961S reveal excitation-coupled calcium entry

(ECCE) is independent of sarcoplasmic reticulum

store depletion. J Biol Chem 280:36994-37004,

2005.

200. Putney JW Jr, Broad LM, Braun FJ, et al: Mecha-

nisms of capacitative calcium entry. J Cell Sci

114:2223-2229, 2001.

201. Kurebayashi N, Ogawa Y: Depletion of Ca

+ in the

sarcoplasmic reticulum stimulates Ca

+ entry into

mouse skeletal muscle fibres. J Physiol 533:185-199,

2001.

202. Ma J, Pan Z: Junctional membrane structure and

store operated calcium entry in muscle cells. Front

Biosci 8:d242-d255, 2003.

203. Pan Z, Yang D, Nagaraj RY, et al: Dysfunction of

store-operated calcium channel in muscle cells

lacking mg29. Nat Cell Biol 4:379-383, 2002.

204. Zhao X,Weisleder N, Han X, et al: Azumolene inhi-

bits a component of store-operated calcium entry

coupled to the skeletal muscle ryanodine receptor.

J Biol Chem 281:33477-33486, 2006.

205. Yamaguchi N, Igami K, Kasai M: Kinetics of depo-

larization-induced calcium release from skeletal

muscle triads in vitro. J Biochem (Tokyo) 121:432-

439, 1997.

206. Paul-Pletzer K,Yamamoto T, Bhat MB, et al: Identi-

fication of a dantrolene-binding sequence on the

skeletal muscle ryanodine receptor. J Biol Chem

277:34918-34923, 2002.

207. Monnier N, Procaccio V, Stieglitz P, Lunardi J:

Malignant-hyperthermia susceptibility is associated

with a mutation of the alpha 1-subunit of the

human dihydropyridine-sensitive L-type voltage-

dependent calcium-channel receptor in skeletal

muscle. Am J Hum Genet 60:1316-1325, 1997.

208. Sambuughin N, Sei Y, Gallagher KL, et al: North

American malignant hyperthermia population:

Screening of the ryanodine receptor gene and iden-

tification of novel mutations. Anesthesiology

95:594-599, 2001.

209. Brown RL, Pollack AN, Couchman KG, et al: A

novel ryanodine receptor mutation and genotype-

phenotype correlation in a large malignant hyper-

thermia New Zealand Maori pedigree. Hum Mol

Genet 9:1515-1524, 2000.

210. Girard T, Urwyler A, Censier K, et al: Genotype-

phenotype comparison of the Swiss malignant

hyperthermia population. Hum Mutat 18:357-358,

2001.

211. Brandt A, Schleithoff L, Jurkat-Rott K, et al: Scree-

ning of the ryanodine receptor gene in 105 malig-

nant hyperthermia families: Novel mutations and

concordance with the in vitro contracture test.Hum

Mol Genet 8:2055-2062, 1999.

212. Rueffert H,Olthoff D,Deutrich C,et al:A newmuta-

tion in the skeletal ryanodine receptor gene (

RYR1

)

is potentially causative of malignant hyperthermia,

central core disease, and severe skeletal malforma-

tion. Am J Med Genet A 124:248-254, 2004.

213. Robinson R, Hopkins P, Carsana A, et al: Several

interacting genes influence the malignant hyper-

thermia phenotype. Hum Genet 112:217-218,

2003.

214. Gillard EF, Otsu K, Fujii J, et al: A substitution of

cysteine for arginine 614 in the ryanodine receptor

is potentially causative of human malignant hyper-

thermia. Genomics 11:751-755, 1991.

215. Sei Y, Sambuughin NN, Davis EJ, et al: Malignant

hyperthermia in North America: Genetic screening

of the three hot spots in the type I ryanodine recep-

tor gene. Anesthesiology 101:824-830, 2004.

216. Davis M, Brown R, Dickson A, et al: Malignant

hyperthermia associated with exercise-induced

rhabdomyolysis or congenital abnormalities and a

novel

RYR1

mutation in New Zealand and Austra-

lian pedigrees. Br J Anaesth 88:508-515, 2002.

217. Oyamada H, Oguchi K, Sitoh N, et al: Novel muta-

tions in C-terminal channel region of the ryanodine

receptor in malignant hyperthermia patients. Jpn J

Pharmacol 88:159-166, 2002.

218. Yeh HM, Tsai MC, Su YN, et al: Denaturing high

performance liquid chromatography screening of

ryanodine receptor type 1 gene in patients with

malignant hyperthermia in Taiwan and identifica-

tion of a novel mutation (Y522C). Anesth Analg

101:1401-1406, 2005.

219. Monnier N, Krivasic-Horber R, Payen JF, et al: Pre-

sence of two different genetic traits in malignant

hyperthermia families: Implication for genetic

analysis, diagnosis, and incidence of malignant

hyperthermia

susceptibility.

Anesthesiology

97:1067-1074, 2002.

220. Fletcher JE, Tripolitis L, Hubert M, et al: Genotype

and phenotype relationships for mutations in the

ryanodine receptor in patients referred for diagno-

sis of malignant hyperthermia. Br J Anaesth 75:307-

310, 1995.

221. Lynch PJ, Krivasic-Horber R, Reyford H, et al: Iden-

tification of heterozygous and homozygous indivi-

duals with the novel

RYR1

mutation Cys35Arg in a

large kindred. Anesthesiology 86:620-626, 1997.

222. Monnier N, Ferreiro A, Marty I, et al: A homo-

zygous splicing mutation causing a depletion of

skeletal muscle RYR1 is associated with multi-mini-

core disease congenital myopathy with ophthalmo-

plegia. Hum Mol Genet 12:1171-1178, 2003.

223. Rueffert H, Olthoff, Deutrich C, et al: Homozygous

andheterozygousArg614Cysmutations(1840C

→

in the ryanodine receptor gene co-segregate with

malignant hyperthermia susceptibility in a German

family. Br J Anaesth 87:240-245, 2001.

224. Zhou H, Brockington M, Jungbluth H, et al: Epige-

netic allele silencing unveils recessive

RYR1

muta-

tions in core myopathies. Am J Hum Genet

79:859-868, 2006.

225. Urwyler A, Deufel T, McCarthy T, et al: Guidelines

for molecular genetic detection of susceptibility to

malignant hyperthermia. Br J Anaesth 86:283-287,

2001.

226. Robinson RL, Brooks C, Brown SL, et al:

RYR1

mutations causing central core disease are associa-

ted with more severe malignant hyperthermia in

vitro contracture test phenotypes. Hum Mutat

20:88-97, 2002.

227. Rueffert H, Othoff D, Deutrich C, et al: Mutation

screening in the ryanodine receptor 1 gene (

RYR1

)

in patients susceptible to malignant hyperthermia

who show definite IVCT results: Identification of

three novel mutations. Acta Anaesthesiol Scand

46:692-698, 2002.

228. Allen GC, Brubaker CL: Human malignant hyper-

thermia associated with desflurane anesthesia.

Anesth Analg 86:1328-1331, 1998.

229. Shulman M, Braverman B, Ivankovich AD, Gronert

G: Sevoflurane triggers malignant hyperthermia in

swine. Anesthesiology 54:259-260, 1981.

230. Gronert GA: Malignant hyperthermia. Anesthesio-

logy 53:395-423, 1980.

231. Hall GM, Lucke JN, Lister D: Proceedings: Neuro-

muscular blocking drugs in porcine malignant

hyperthermia. Br J Anaesth 48:270-271, 1976.

232. Denborough M, Hopkinson KC: Propofol and

malignant hyperpyrexia. Lancet 1:191, 1988.

233. Bendixen D, Skovgaard LT, Ording H: Analysis of

anaesthesia in patients suspected to be susceptible

to malignant hyperthermia before diagnostic in

vitro contracture test. Acta Anaesthesiol Scand

41:480-484, 1997.

234. Larach MG, Localio AR, Allen GC, et al: A clinical

grading scale to predict malignant hyperthermia

susceptibility. Anesthesiology 80:771-779, 1994.

235. Rosenberg H, Davis M, James D, et al: Malignant

hyperthermia. Orphanet J Rare Dis 2:21, 2007.

236. Antognini JF: Creatine kinase alterations after acute

malignant hyperthermia episodes and common sur-

gical procedures. Anesth Analg 81:1039-1042, 1995.

237. Wappler F, Fiege M, Steinfath M, et al: Evidence for

susceptibility to malignant hyperthermia in patients

with exercise-induced rhabdomyolysis.Anesthesio-

logy 94:95-100, 2001.

238. Anetseder M, Hartung E, Klepper S, Reichmann H:

Gasoline vapors induce severe rhabdomyolysis.

Neurology 44:2393-2395, 1994.

239. Denborough MA, Hopkinson KC, Banney DG:

Firefighting and malignant hyperthermia. BMJ

(Clin Res Ed) 296:1442-1443, 1988.

240. Ryan JF, Tedeschi LG: Sudden unexplained death in

a patient with a family history of malignant hyper-

thermia. J Clin Anesth 9:66-68, 1997.

241. Butler-Browne GS, Eriksson PO, Laurent C, Thor-

nell LE:Adult humanmasseter muscle fibers express

myosin isozymes characteristic of development.

Muscle Nerve 11:610-620, 1988.

242. Morgan DL, Proske U: Vertebrate slow muscle: Its

structure, pattern of innervation, and mechanical

properties. Physiol Rev 64:103-169, 1984.

243. van der Spek AF, Reynolds PI, Fang WB, et al:

Changes in resistance to mouth opening induced by

depolarizing and non-depolarizing neuromuscular

relaxants. Br J Anaesth 64:21-27, 1990.

244. Flewellen EH, Nelson TE, Jones WP, et al: Dantro-

lene dose response in awake man: Implications for

management of malignant hyperthermia. Anesthe-

siology 59:275-280, 1983.

245. Lerman J, McLeod ME, Strong HA: Pharmacokine-

tics of intravenous dantrolene in children.Anesthe-

siology 70:625-629, 1989.

246. Burkman JM, Posner KL, Domino KB: Analysis of

the clinical variables associated with recrudescence

after malignant hyperthermia reactions. Anesthe-

siology 106:901-906, quiz 1077-1078, 2007.

247. Hopkins PM: Recrudescence of malignant hyper-

thermia. Anesthesiology 106:893-894, 2007.

960

Control de la anestesia

III